Evaluation of a protocol for rifaximin discontinuation in critically ill patients with liver disease receiving broad-spectrum antibiotic therapy.

Ward, Jessica A; Yerke, Jason; Lumpkin, Mollie; Kapoor, Aanchal; Lindenmeyer, Christina C; Bass, Stephanie

Ward, Jessica A; Yerke, Jason; Lumpkin, Mollie; Kapoor, Aanchal; Lindenmeyer, Christina C; Bass, Stephanie.

Afiliación

Ward JA; Department of Pharmacy, Cleveland Clinic, Cleveland, OH 44195, United States. wardj4@ccf.org.
Yerke J; Department of Pharmacy, Cleveland Clinic, Cleveland, OH 44195, United States.
Lumpkin M; Department of Pharmacy, Cleveland Clinic, Cleveland, OH 44195, United States.
Kapoor A; Department of Critical Care Medicine, Cleveland Clinic, Cleveland, OH 44195, United States.
Lindenmeyer CC; Department of Gastroenterology, Hepatology, and Nutrition, Cleveland Clinic, Cleveland, OH 44195, United States.
Bass S; Department of Pharmacy, Cleveland Clinic, Cleveland, OH 44195, United States.

World J Hepatol ; 15(11): 1226-1236, 2023 Nov 27.

Article en En | MEDLINE | ID: mdl-38075005

Palabras clave

Antibiotics; Cirrhosis; Critical illness; Hepatic encephalopathy; Liver disease; Rifaximin

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: World J Hepatol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google